112 related articles for article (PubMed ID: 32687349)
1. Interdimeric Curvature in Tubulin-Tubulin Complexes Delineates the Microtubule-Destabilizing Properties of Plocabulin.
Navarrete KR; Jiménez VA
J Chem Inf Model; 2020 Aug; 60(8):4076-4084. PubMed ID: 32687349
[TBL] [Abstract][Full Text] [Related]
2. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents.
Zúñiga MA; Alderete JB; Jaña GA; Fernandez PA; Ramos MJ; Jiménez VA
Chem Biol Drug Des; 2018 May; 91(5):1042-1055. PubMed ID: 29316292
[TBL] [Abstract][Full Text] [Related]
3. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin.
Pantazopoulou A; Galmarini CM; Peñalva MA
Sci Rep; 2018 Jun; 8(1):8616. PubMed ID: 29872155
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of the analogs of plocabulin and their preliminary structure-activity relationship study.
Wang L; Li X; Cui H; Lei X; Liu H; Wang Q; Li Y
Bioorg Med Chem Lett; 2021 Nov; 51():128355. PubMed ID: 34508844
[TBL] [Abstract][Full Text] [Related]
6. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
[TBL] [Abstract][Full Text] [Related]
8. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-Based Rational Discovery and
Zúñiga-Bustos M; Vásquez PA; Jaña GA; Guzmán JL; Alderete JB; Jiménez VA
J Chem Inf Model; 2020 Jun; 60(6):3204-3213. PubMed ID: 32286822
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling study on the differential microtubule-stabilizing effect in singly- and doubly-bonded complexes with peloruside A and paclitaxel.
Zúñiga MA; Alderete JB; Jaña GA; Navarrete KR; Jiménez VA
Proteins; 2019 Aug; 87(8):668-678. PubMed ID: 30958582
[TBL] [Abstract][Full Text] [Related]
11. Rational Discovery of Microtubule-Stabilizing Peptides.
Úsuga-Acevedo B; García Y; Díaz CF; Jiménez VA
J Chem Inf Model; 2022 Dec; 62(24):6844-6856. PubMed ID: 36074453
[TBL] [Abstract][Full Text] [Related]
12. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
[TBL] [Abstract][Full Text] [Related]
13. Effect of the Marine Polyketide Plocabulin on Tumor Progression.
Turrini E; Maffei F; Fimognari C
Mar Drugs; 2022 Dec; 21(1):. PubMed ID: 36662211
[TBL] [Abstract][Full Text] [Related]
14. Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
Wang Y; Wozniak A; Cornillie J; Avilés P; Debiec-Rychter M; Sciot R; Schöffski P
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806460
[TBL] [Abstract][Full Text] [Related]
15. Pironetin Binds Covalently to αCys316 and Perturbs a Major Loop and Helix of α-Tubulin to Inhibit Microtubule Formation.
Prota AE; Setter J; Waight AB; Bargsten K; Murga J; Diaz JF; Steinmetz MO
J Mol Biol; 2016 Jul; 428(15):2981-8. PubMed ID: 27395016
[TBL] [Abstract][Full Text] [Related]
16. Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy.
Cao S; Dong YH; Wang DF; Liu ZP
Curr Med Chem; 2020; 27(27):4567-4576. PubMed ID: 32175831
[TBL] [Abstract][Full Text] [Related]
17. New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism.
Pera B; Barasoain I; Pantazopoulou A; Canales A; Matesanz R; Rodriguez-Salarichs J; García-Fernandez LF; Moneo V; Jiménez-Barbero J; Galmarini CM; Cuevas C; Peñalva MA; Díaz JF; Andreu JM
ACS Chem Biol; 2013 Sep; 8(9):2084-94. PubMed ID: 23859655
[TBL] [Abstract][Full Text] [Related]
18. Effect of amino acid mutations on intra-dimer tubulin-tubulin binding strength of microtubules.
Liu N; Pidaparti R; Wang X
Integr Biol (Camb); 2017 Dec; 9(12):925-933. PubMed ID: 29114690
[TBL] [Abstract][Full Text] [Related]
19. How tubulin subunits are lost from the shortening ends of microtubules.
Tran PT; Joshi P; Salmon ED
J Struct Biol; 1997 Mar; 118(2):107-18. PubMed ID: 9126637
[TBL] [Abstract][Full Text] [Related]
20. PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.
Martínez-Díez M; Guillén-Navarro MJ; Pera B; Bouchet BP; Martínez-Leal JF; Barasoain I; Cuevas C; Andreu JM; García-Fernández LF; Díaz JF; Avilés P; Galmarini CM
Biochem Pharmacol; 2014 Apr; 88(3):291-302. PubMed ID: 24486569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
